所有图片(1)

文件

M7824

甲氨蝶呤

Name: 甲氨蝶呤
Brand: SIGMA

登录查看公司和协议定价

所有图片(1)

别名:

甲氨蝶呤, (+)-氨甲蝶呤, 4-氨基-N¹⁰-甲基巯基-L-谷氨酸, MTX, 氟安定, 氨甲叶酸, 氨甲喋呤

经验公式（希尔记法）:

C₂₀H₂₂N₈O₅

CAS号:

59-05-2

分子量:

454.44

Beilstein:

70669

EC 号:

200-413-8

MDL编号:

MFCD00064370

NACRES:

NA.21

生物来源

synthetic

质量水平

400

形式

powder

适用性

suitable for manufacturing use

储存温度

−20°C

SMILES string

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

InChI key

FBOZXECLQNJBKD-ZDUSSCGKSA-N

Gene Information

human ... DHFR(1719)

正在寻找类似产品? Visit 产品对比指南

一般描述

我们用于生物制药加工的SAFC^® 系列优质原料经过严格的质量控制流程，配合记录文件和技术专长帮助我们的客户达到M-Clarity Program规定的要求。

M-Clarity Program

我们全面的上游工艺化学品系列不仅为生物制药生产商提供生产传统和创新治疗药物所需的优质原料，而且帮助他们更快地将产品投放市场并简化监管问题。请相信我们能够为您带来透明的供应链和可靠的全球采购能力，以最佳的法规支持和服务简化您的产品认证。

抑制胸苷酸合成酶，是一种非选择性的嘌呤从头合成抑制剂，具有显著的毒性特征，包括肝毒性、肺炎和骨髓抑制。强效叶酸拮抗剂。在HL-60人白血病细胞中诱导凋亡。还可用作抗肿瘤剂。

法律信息

SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

GHS06,GHS08

警示用语：

Danger

危险声明

H301 - H315 - H319 - H341 - H360D

预防措施声明

P202 - P264 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338

危险分类

Acute Tox. 3 Oral - Eye Irrit. 2 - Muta. 2 - Repr. 1B - Skin Irrit. 2

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503

货号

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

Roy Fleischmann et al.

Annals of the rheumatic diseases, 74(6), 1132-1137 (2014-08-22)

Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28-CRP have not been validated.

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.

Miguel Perez-Aso et al.

Arthritis research & therapy, 17, 249-249 (2015-09-16)

This work was undertaken to delineate intracellular signaling pathways for the PDE4 inhibitor apremilast and to examine interactions between apremilast, methotrexate and adenosine A2A receptors (A2AR). After apremilast and LPS incubation, intracellular cAMP, TNF-α, IL-10, IL-6 and IL-1α were measured

Deep sequencing reveals different compositions of mRNA transcribed from the F8 gene in a panel of FVIII-producing CHO cell lines.

Christian S Kaas et al.

Biotechnology journal, 10(7), 1081-1089 (2015-05-13)

Coagulation factor VIII (FVIII) is one of the most complex biopharmaceuticals due to the large size, poor protein stability and extensive post-translational modifications. As a consequence, efficient production of FVIII in mammalian cells poses a major challenge, with typical yields

Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.

Anna-Birgitte Aga et al.

Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)

To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with

Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial.

Axel Finckh et al.

Arthritis research & therapy, 16(5), 458-458 (2014-10-16)

Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件